Cadila Healthcare gains on acquiring 50% shares of Zydus BSV Pharma

Cadila Healthcare is currently trading at Rs. 1696.40, up by 35.15 points or 2.12% from its previous closing of Rs. 1661.25 on the BSE. The scrip opened at Rs. 1686.65 and has touched a high and low of Rs. 1706.85 and Rs. 1686.65 respectively. So far 1,943 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1760.00 on 11-Nov-2014 and a 52 week low of Rs. 872.55 on 19-May-2014. Last one week high and low of the scrip stood at Rs. 1714.70 and Rs. 1585.00 respectively. The current market cap of the company is Rs. 34,795.00 crore. The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 14.65% and 10.56% respectively. Cadila Healthcare has purchased 50% shares of Zydus BSV Pharma from Bharat Serums and Vaccines and now Zydus BSV has become 100% subsidiary of Cadila Healthcare. Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.